Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Historical Holders from Q1 2021 to Q3 2025

Symbol
CGEM on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
58,837,653
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
61,075,479
Holdings value
$362,176,402
% of all portfolios
0.002%
Number of holders
142
Number of buys
82
Number of sells
-62
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 14.5% +100% $50,697,778 +$24,599,905 8,549,084 +94.3% Lynx1 Capital Management LP 08 Oct 2025
VANGUARD GROUP INC 4.98% $17,453,917 2,943,325 The Vanguard Group 30 Sep 2025
Flynn James E 4.95% $17,357,187 2,927,013 Deerfield Mgmt, L.P. 30 Sep 2025
FRANKLIN RESOURCES INC 3.8% $17,836,873 2,191,262 Franklin Resources, Inc. 30 Sep 2024
CITADEL ADVISORS LLC 3.4% -34% $11,794,219 -$6,049,899 1,988,907 -33.9% Kenneth Griffin 30 Sep 2025

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 61,075,479 $362,176,402 -$12,503,421 $5.93 142
2025 Q2 62,610,123 $471,432,056 -$15,598,491 $7.53 141
2025 Q1 64,669,430 $489,559,204 -$25,799,469 $7.57 145
2024 Q4 65,580,571 $798,774,691 -$43,310,126 $12.18 144
2024 Q3 65,000,732 $1,087,002,831 -$1,185,148 $16.74 136
2024 Q2 62,920,773 $1,097,340,923 +$411,767,308 $17.44 134
2024 Q1 39,359,979 $670,698,022 +$49,224,262 $17.04 113
2023 Q4 36,858,851 $375,589,972 +$26,958,804 $10.19 110
2023 Q3 38,010,712 $344,003,620 +$11,040,871 $9.05 104
2023 Q2 36,693,312 $394,818,289 +$48,696,476 $10.76 102
2023 Q1 32,209,329 $329,495,842 -$56,320,751 $10.23 97
2022 Q4 37,711,425 $397,852,399 +$5,318,094 $10.55 94
2022 Q3 37,032,227 $474,756,845 -$7,043,826 $12.82 94
2022 Q2 37,570,810 $481,656,895 +$20,400,666 $12.82 81
2022 Q1 36,763,865 $384,914,646 +$4,824,538 $10.47 77
2021 Q4 36,386,962 $559,714,828 +$6,266,769 $15.43 74
2021 Q3 33,862,280 $762,265,836 +$33,803,888 $22.57 63
2021 Q2 32,250,659 $828,539,736 -$17,650,444 $25.75 70
2021 Q1 31,323,171 $1,298,948,827 +$1,298,948,827 $41.67 70